| Document |
Document Title |
|
WO/2019/046848A1 |
Herein polymers and particles which comprise a plurality of dihydropyridazine or hydropyridazine functional groups are described. Methods for their formation and specific monomers which may be used in their formation are also described. ...
|
|
WO/2019/045824A1 |
The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of inhibiting ROCK1 and/or ROCK2 that are useful for the treatment of disease.
|
|
WO/2019/034692A1 |
The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of...
|
|
WO/2019/034693A1 |
The present invention relates to sulfonylureas and sulfonylthioureas comprising a monocyclic imidazolyl group. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions compri...
|
|
WO/2019/025554A1 |
The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)- one derivatives of formula (I) : The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)- one derivatives of formula (I) :
|
|
WO/2019/025467A1 |
The present disclosure relates to compounds of Formula (I): (I); and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful fo...
|
|
WO/2019/023553A1 |
The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to ...
|
|
WO/2019/008029A1 |
The present invention relates to compounds of formula (I): wherein Q is O or S, R1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R1 may optionally be substituted, and R2 ...
|
|
WO/2019/002173A1 |
The present invention relates to a compound of formula (I): wherein the meanings for the various substituents are as disclosed in the description, having dual pharmacological activity towards both the α2δ subunit, in particular the α2...
|
|
WO/2019/005484A1 |
Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, Formula (1) wherein W, R1, R2, R3, n, R4, R5, R6, L and G are as defined in the disclosure. Also disclosed are compositions containing the co...
|
|
WO/2017/191000A9 |
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...
|
|
WO/2018/234346A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
|
|
WO/2018/221433A1 |
Provided is a novel compound, and a pharmaceutically acceptable salt thereof, that has an action of reducing blood sugar and the like, and that is useful as a therapeutic and/or preventive medicine for diseases such as diabetes. Provided...
|
|
WO/2018/214736A1 |
Provided are a polyhydroxyphthalazinone compound, a preparation method therefor and the use thereof, wherein the general formula of the chemical structure of the polyhydroxyphthalazinone compound is as shown by formula (I). The polyhydro...
|
|
WO/2018/213150A1 |
The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mi...
|
|
WO/2018/210296A1 |
The present invention relates to a use of an EZH2 inhibitor combined with a BTK inhibitor in preparing a drug for treating a tumor.
|
|
WO/2018/195439A2 |
Provided herein, inter alia, are methods and compounds for modulating K-Ras treating cancer.
|
|
WO/2018/183432A1 |
Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, agricultural compositions containing them and their use as herbicides (Formula 1), wherein R1, R2, L, G and W are as defined in the disclusur...
|
|
WO/2018/183587A1 |
The present invention generally relates to 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles as a ubiquitin specific protease 7 (USP7) inhibitor useful for the treatment of diseases mediated by malfunction of USP7, such as inflammation, cancer...
|
|
WO/2018/177126A1 |
A phthalazone hydroxamic acid compound, a preparation method therefor and an application thereof. A structural formula of the compound is represented by formula I: (I), wherein R1 and R2 are hydrogen atoms or halogen, Y is an oxygen atom...
|
|
WO/2018/167468A1 |
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the matura...
|
|
WO/2018/167800A1 |
The present invention relates to fused bicyclic compounds that are inhibitors of GPR91, their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them. T...
|
|
WO/2018/165615A1 |
The invention is directed to roles for PARP-1 in disease.
|
|
WO/2018/157232A1 |
Compositions comprising modulators of N-terminus activation of the androgen receptor, such as EPI-002 and EPI-506, and a second therapeutic agent are provided. Use of such compositions for treatment of various indications, including pros...
|
|
WO/2018/153279A1 |
The present invention provides novel dihydropyridophthalazinone compounds of Formula (I) as PARP inhibitors, and their pharmaceutically acceptable salts, solvates, hydrates, prodrugs and metabolites thereof, the preparation thereof, and ...
|
|
WO/2018/149991A1 |
The present invention relates to particular sulfonamide derivatives, the pharmaceutically acceptable addition salts thereof, the hydrates thereof and/or the solvates thereof, and also the use thereof as inverse agonists of retinoid-relat...
|
|
WO/2018/146010A1 |
The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I), in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds us...
|
|
WO/2018/140512A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, isotopic form, stereoisomer or prodrug thereof, wherein A, B, X,...
|
|
WO/2018/133579A1 |
Provided in the present invention are a ruthenium metal complex of which the molecular formula is L3Ir, applications thereof, and an organic electroluminescent component, where Ir is the center metal atom, L is a ligand, and the structur...
|
|
WO/2018/131690A1 |
[Problem] To provide a novel agrochemical, especially a novel herbicide. [Solution] A ketone or oxime compound represented by formula (1), and a herbicide which contains this compound. (In the formula, B represents B-1 or B-2; Q represen...
|
|
WO/2018/128084A1 |
Provided is a polymerizable compound that has low-wavelength dispersion or reverse-wavelength dispersion, does not readily bubble when made into a coating material, has excellent substrate adhesion when made into a film-like polymer, and...
|
|
WO/2018/115069A1 |
The present invention relates to new compounds of formula (I): showing great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC),especially the α2δ-1 subunit of voltage-gated calcium channels or dua...
|
|
WO/2018/116107A1 |
Provided are IDO inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases ...
|
|
WO/2018/111787A1 |
Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause...
|
|
WO/2018/106284A1 |
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or condit...
|
|
WO/2018/093696A1 |
The present invention relates to a compound represented by formula I': and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 ("DGAT2") and may be useful in the tre...
|
|
WO/2018/085813A1 |
Disclosed herein are thieno[2,3-b:5,4-c']dipyridin-8-amine and pyrido[4',3':4,5]thieno[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also ...
|
|
WO/2018/082964A1 |
Process for the production of compounds (I). their salts, tautomers, or enantiomers; by reaction of compounds (II) their salts, tautomers, or enantiomers; with compounds (III) their salts, tautomers, or enantiomers. And compounds III in ...
|
|
WO/2018/081377A1 |
The present disclosure is directed to compounds that modulate, e.g., address underlying defects in cellular processing of CFTR (cystic fibrosis transmembrane conductance regulator) activity.
|
|
WO/2018/080216A1 |
The present invention relates to a compound represented by Chemical Formula 1, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of cardiov...
|
|
WO/2018/077875A1 |
The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein R1a, R1b, R2, X, A, Ra, Rb, Rc, Rd and m are as defined herein. The invention further relates to herbicidal composit...
|
|
WO/2018/081378A1 |
The present disclosure is directed to pyridazinone derivatives of generic formula that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
|
|
WO/2018/068296A1 |
Piperidine compounds of the Formular: (I) and pharmaceutically acceptable salts thereof, wherein X, Y, R 1, R 2, R 3, L, R 4, L 1, Q and R 5 are as defined herein. The compounds and pharmaceutically acceptable compositions comprising a c...
|
|
WO/2018/068282A1 |
Provided are compounds of formula (I),wherein R 1, Y, X 1, X 2, R 2, R 3, R 4, R 5, R 6 and m have any of the values defined in the specification and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment o...
|
|
WO/2018/060575A1 |
The invention relates to compositions comprising 1-chloro-2,2-difluoroethane, and the uses thereof.
|
|
WO/2018/056868A1 |
The invention relates to medicine and more particularly to drugs which act upon the immune system and have immunomodulatory, anti-inflammatory, anti-tumour and anti-oxidant activity, as well as to the chemical pharmaceutical production o...
|
|
WO/2018/051252A2 |
An object of the present invention is to provide an amide compound or a salt thereof that controls a mite. The present invention provides an amide compound represented by Formula (1) : or a salt thereof, wherein R1 represents C1-6 alkyl ...
|
|
WO/2018/045969A1 |
Disclosed is a compound as represented by formula I. The compound is used as an activator for adenosine monophosphate-activated protein kinase to phosphorylate and activate adenosine monophosphate-activated protein kinase, and then to re...
|
|
WO/2018/049271A1 |
Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of chemokine receptor activity.
|
|
WO/2018/038668A1 |
Compounds of Formula (I): wherein W is NR1A or CR1BR1B; Z is N or CH, R1A is C1-C3alkyl, C1-C3haloalkyl, C3-C4cycloalkyl or phenyl wherein cycloalkyl or phenyl is optionally mono-, di- or tri-substituted with substituents each independen...
|
